Sandbox: malabsorption: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
!
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
| colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" |'''Clinical manifestation'''
| colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" |'''Clinical manifestation'''
Line 12: Line 11:
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Gold standard diagnosis
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Gold standard diagnosis
|-
|-
!
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" |Symptoms
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" |Symptoms
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Signs
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Signs
|-
|-
!
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Diarrhea
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Diarrhea
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Fever
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Fever
Line 23: Line 20:
!
!
|-
|-
!
! align="center" style="background:#4479BA; color: #FFFFFF;" |Watery
! align="center" style="background:#4479BA; color: #FFFFFF;" |Watery
! align="center" style="background:#4479BA; color: #FFFFFF;" |Bloody
! align="center" style="background:#4479BA; color: #FFFFFF;" |Bloody
Line 32: Line 28:
! align="center" style="background:#4479BA; color: #FFFFFF;" |Other lab findings
! align="center" style="background:#4479BA; color: #FFFFFF;" |Other lab findings
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 65: Line 60:
* [[PCR]] testing
* [[PCR]] testing
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
Line 99: Line 93:
* [[IgA]] tissue transglutaminase antibody
* [[IgA]] tissue transglutaminase antibody
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 126: Line 119:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 153: Line 145:
* [[Colonoscopy]] with [[biopsy]]
* [[Colonoscopy]] with [[biopsy]]
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 188: Line 179:
* [[Colonoscopy]] with [[biopsy]]
* [[Colonoscopy]] with [[biopsy]]
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 215: Line 205:
* Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L
* Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 249: Line 238:
* Followed by imaging
* Followed by imaging
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 272: Line 260:
* Elevated basal or stimulated serum [[gastrin]]> 120 pg/mL
* Elevated basal or stimulated serum [[gastrin]]> 120 pg/mL
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 298: Line 285:
* [[Eosinophilic]] infiltration of the [[gastrointestinal tract]] on [[biopsy]]
* [[Eosinophilic]] infiltration of the [[gastrointestinal tract]] on [[biopsy]]
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 321: Line 307:
* Positive [[SeHCAT]]
* Positive [[SeHCAT]]
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 349: Line 334:
* Clinical findings and low [[triglyceride]] and [[cholesterol]] level
* Clinical findings and low [[triglyceride]] and [[cholesterol]] level
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 381: Line 365:
** [[Lymphocytic]] [[colitis]] is characterized by ≥20 intraepithelial [[lymphocytes]] (IEL) per 100 surface epithelial cells
** [[Lymphocytic]] [[colitis]] is characterized by ≥20 intraepithelial [[lymphocytes]] (IEL) per 100 surface epithelial cells
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 412: Line 395:
* [[TSH]]
* [[TSH]]
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 440: Line 422:
* [[Lactase]] activity assay
* [[Lactase]] activity assay
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 461: Line 442:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 479: Line 459:
* [[Secretin]] stimulation test
* [[Secretin]] stimulation test
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 496: Line 475:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 513: Line 491:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 530: Line 507:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 547: Line 523:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 564: Line 539:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 581: Line 555:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 598: Line 571:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 615: Line 587:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
!
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 632: Line 603:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! rowspan="4" |[[Infection]]
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  

Revision as of 16:20, 29 November 2017

Abbreviations: WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A

Cause Clinical manifestation Lab findings Additional findings Cause/Pathogenesis Gold standard diagnosis
Symptoms Signs
Diarrhea Fever Abdominal pain Weight loss
Watery Bloody Fatty WBC Hgb Plt Other lab findings
Whipple's disease + - + ± + + ↓/↑
Celiac disease ± - ± - + + - -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Tropical sprue + - + + + + - -
  • Diagnosis of exclusion
Crohns disease + + + + + +
  • Abnormal immune response to self antigens
Ulcerative colitis + + + + + +
  • Hypoalbuminemia
  • Hypokalemia
  • Hypomagnesemia
  • Iron deficiency
  • Elevated ESR
  • Elevated CRP
  • Abnormal immune response to self antigens
Cystic fibrosis - - + ± + + - -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
VIPoma + - + - + + - - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome + - + - + + - -
  • Elevated basal or stimulated serum gastrin> 120 pg/mL
Eosinophilic gastroenteritis  + - + - + + - -
Primary bile acid malabsorption + - + - + + - -
Abetalipoproteinemia + - + - + + - - -
Microscopic colitis + + - - + + - -
Hyperthyroidism + - - ± + + - - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Lactose intolerance + - - - + - - - -
Irritable bowel syndrome ± - ± - ± - - - -
  • Diagnosis of exclusion
Chronic pancreatitis + - + - + +
Cirrhosis + - + + + +
Short bowel syndrome -
Intestinal lymphoma
Agammaglobulinemia
Intestinal lymphangiectasia
Amyloidosis
Mastocytosis
Small intestinal bacterial overgrowth
Drug induced enteritis
HIV infection
Giardiasis
Strongyloidiasis
Tuberculosis